Understand this story
On October 22, 2026, Phylo, Inc. announced a partnership with Bayer to deploy the Biomni Lab agentic AI platform. According to a Unite.AI report, Bayer scientists will receive full access to the platform for literature and omics evidence workflows in drug discovery. Phylo states that the platform integrates scientific literature, biomedical data, and analytical methods into a single environment, with each result retaining provenance, methods, and execution details to facilitate researcher verification and reproducibility. The report also mentions that Biomni Lab shares the same origin as the Stanford open-source project Biomni, and that the enterprise edition provides dedicated infrastructure, custom agents, and advanced security features. There are currently no subsequent development facts.
AI-generated from public reports
Latest development · Report
Phylo Partners with Bayer to Accelerate Drug Discovery with Biomni Lab AI AgentsDevelopments
1 confirmed developments
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Oct 23
Unite.AI
Phylo Partners with Bayer to Accelerate Drug Discovery with Biomni Lab AI Agents
On October 22, 2026, Phylo announced a partnership with Bayer. Bayer scientists will gain full access to the Biomni Lab agentic AI platform for literature and omics evidence workflows in drug discovery. Phylo states that the platform integrates scientific literature, biomedical data, and analytical methods into a single environment, with every result retaining its source, methods, and execution details so researchers can verify and reproduce it. Biomni Lab shares the same origin as Stanford's open-source Biomni project, and the enterprise edition offers dedicated infrastructure, custom agents, and advanced security features.